Hereditary diffuse leukoencephalopathy with spheroids (HDLS)
is an autosomal-dominant central nervous system whitematter disease with variable clinical presentations, including personality and behavioral changes, dementia, depression, parkinsonism, seizures and other phenotypes 1,2 . We combined genome-wide linkage analysis with exome sequencing and identified 14 different mutations affecting the tyrosine kinase domain of the colony stimulating factor 1 receptor (encoded by CSF1R) in 14 families with HDLS. In one kindred, we confirmed the de novo occurrence of the mutation. Followup sequencing identified an additional CSF1R mutation in an individual diagnosed with corticobasal syndrome. In vitro, CSF-1 stimulation resulted in rapid autophosphorylation of selected tyrosine residues in the kinase domain of wild-type but not mutant CSF1R, suggesting that HDLS may result from partial loss of CSF1R function. As CSF1R is a crucial mediator of microglial proliferation and differentiation in the brain, our findings suggest an important role for microglial dysfunction in HDLS pathogenesis.
HDLS typically presents as an autosomal-dominant disease associated with variable behavioral, cognitive and motor changes [1] [2] [3] . The onset of symptoms is usually in the fourth or fifth decade, progressing to dementia with death within 6 years. In magnetic resonance imaging (MRI), HDLS is characterized by patchy abnormalities in cerebral white matter, often initially asymmetrical but becoming confluent and symmetrical with disease progression [4] [5] [6] [7] [8] [9] [10] [11] [12] . The changes predominantly involve the frontal and parietal white matter, with evolving cortical atrophy affecting these lobes ( Fig. 1a,b) . As neither the clinical symptoms nor the MRI changes are specific, a definite diagnosis of HDLS relies on pathological examination showing widespread loss of myelin sheaths and axonal destruction, axonal spheroids, gliosis and autofluorescent lipid-laden macrophages ( Fig. 1c-i) 1,4-8,10-12 . Occasionally, brain biopsy has been used to confirm the diagnosis 9 .
To identify the genetic basis of HDLS, we established an international consortium with ethical approval from the Mayo Clinic Institutional Review Board and collected clinical data, MRI studies and blood and brain tissue samples from families with at least one individual with autopsy-or biopsy-proven HDLS. In total, we collected 14 kindreds from the United States, Norway, Germany and Scotland (Fig. 2) . We selected family VA for genome-wide linkage studies, and using nonparametric linkage analyses we identified one locus with a lod score >2.5 (chromosome 5; lod = 2.67) and four loci with lod scores >1.0 ( Supplementary Fig. 1) . Subsequent parametric linkage analysis identified significant linkage on chromosome 5q34 (lod = 3.71, θ = 0 at rs13178296), whereas none of the other Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids loci reached significance ( Supplementary Fig. 1 ). Obligate recombinants narrowed the candidate region to 30.3 cM between rs801399 and rs1445716 ( Supplementary Fig. 2 ), corresponding to a ~25-Mb genomic interval containing 233 candidate genes.
To generate a list of potential disease-causing mutations, we performed whole-exome sequencing of two pathologically confirmed affected individuals from family VA (VA-21 and VA-24; Fig. 2 ). We generated variant profiles for each affected individual and searched for shared heterozygous variants located within the chromosome 5q candidate region. We further predicted that mutations underlying HDLS are likely to be previously unidentified; therefore, we filtered all of the identified base alterations against dbSNP132. This led to the identification of two nonsynonymous mutations: c.80C>T (p.Ser27Leu) in the gene encoding 5-hydroxytryptamine receptor 4 (HTR4) and c.2624T>C (p.Met875Thr) in CSF1R. Both mutations segregated with disease in the extended family VA and were absent in 660 controls. We therefore searched for additional mutations in a cohort of 13 probands from autopsy-or biopsy-proven HDLS families ( Fig. 2) . Sanger sequencing of the six coding exons of HTR4 and 22 coding exons of CSF1R identified heterozygous CSF1R mutations in all 13 probands, whereas no other mutations in HTR4 were identified ( Fig. 3 and Supplementary Table 1 ). Segregation analyses confirmed transmission of the CSF1R mutations and co-segregation with the disease phenotype in all families for which DNA from multiple affected individuals was available ( Fig. 2) . We further confirmed the de novo occurrence of one CSF1R mutation in monozygotic twins from family NO without a family history of HDLS ( Supplementary Fig. 3) . To confirm the rarity of these mutations and provide supporting evidence for pathogenicity, we also sequenced the CSF1R gene in 24 unrelated controls and genotyped the 13 newly discovered mutations in at least 1,436 controls of European ancestry using TaqMan genotyping assays. None of the mutations identified in subjects with HDLS and no other novel CSF1R mutations were found in controls.
The residues affected by the 14 CSF1R mutations identified in families with HDLS are all located in the intracellular tyrosine kinase domain of CSF1R, encoded by exons 12-22. The mutations include ten missense mutations and one single-codon deletion, all affecting residues highly conserved across species and within members of the CSF1-PDGF receptor family of tyrosine kinases (Kit, FLT3 and PDGFRα/β, ref. 13; Fig. 3 ). We further identified three splice-site mutations, leading to the in-frame deletion of exon 13 (NO) or exon 18 (CA2 and FL2), which removes up to 40 consecutive amino acid residues within the tyrosine kinase domain ( Supplementary Fig. 4 ).
Detailed clinical information was available for 24 individuals with proven CSF1R mutations from 14 HDLS families ( Table 1) . Mean age at onset was 47.2 ± 14.5 years (range 18-78 years), with mean disease duration of 6.0 ± 3.1 years (range 2-11 years) and a mean age at death of 57.2 ± 13.1 years (range 40-84 years). In some families (FL1, CA1 and VA), age at onset or death differed by more than 25 years among family members, whereas a monozygotic twin pair (family NO) showed highly similar disease courses with ages at onset and death within 1 year of each other, suggesting that currently unidentified genetic or environmental factors may be important determinants of the age-related disease penetrance. Presenting features and evolving clinical symptoms also varied substantially within and l e t t e r s npg l e t t e r s across families, and ante mortem clinical diagnoses in mutation carriers included frontotemporal dementia, corticobasal syndrome, Alzheimer's disease, multiple sclerosis, atypical cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and Parkinson's disease.
As most affected people included in our study were not diagnosed with HDLS, we hypothesized that CSF1R mutation carriers may be present in clinical series of early-onset Alzheimer's disease, frontotemporal dementia, corticobasal syndrome, multiple sclerosis and Parkinson's disease, or in individuals affected by ischemic stroke with additional white-matter changes. Sequencing of CSF1R exons 12-22, encoding the protein's tyrosine kinase domain, in up to 93 Mayo Clinic patients affected with these neurological syndromes led to the identification of an additional CSF1R missense mutation, c.2509G>T (p.Asp837Tyr), in a woman with clinical symptoms resembling corticobasal syndrome (Supplementary Tables 2 and 3) . The identification of a CSF1R mutation in this limited patient series underscores the possibility that HDLS may be an underdiagnosed disease.
CSF1R is a cell-surface receptor primarily for the cytokine CSF-1, which regulates the survival, proliferation, differentiation and function of mononuclear phagocytic cells, including microglia of the central nervous system 14 . CSF1R is composed of a highly glycosylated extracellular ligand-binding domain, a transmembrane domain and an intracellular tyrosine kinase domain 15 . Binding of CSF-1 to CSF1R results in the formation of receptor homodimers and subsequent autophosphorylation of several tyrosine residues in the cytoplasmic domain 16 . CSF1R autophosphorylation precedes CSF1R-dependent phosphorylation of several proteins, including the phosphatase SHP-1 and the kinases Src, PLC-γ, PI(3)K, Akt and Erk [16] [17] [18] . In the brain, CSF1R is predominantly expressed in microglial cells, although low levels of CSF1R have been reported in cultured neurons [19] [20] [21] . An increase in CSF1R copy number and point mutations leading to constitutive activation of the CSF1R receptor have been associated with tumor development, including hematological malignancies and renal-cell carcinomas 22, 23 .
To assess the functional importance of the CSF1R mutations identified in this study, we first studied the effects of the mutations on CSF1R in vitro. We transiently expressed DDK-tagged wild-type (CSF1RWT) and mutant (CSF1R E633K, CSF1R M766T or CSF1R M875T) CSF1R in cultured cells. Upon stimulation with CSF-1, we observed autophosphorylation on multiple tyrosine residues for CSF1RWT, whereas none of the mutants showed detectable autophosphorylation ( Fig. 4 and Supplementary Fig. 5 ). As all mutations alter residues in the CSF1R kinase domain, dimerization and/or To protect confidentiality, some individuals are not shown, and sex is portrayed using a diamond for all individuals except affected individuals and their spouses. In each family, at least one affected family member received an autopsy (red hash sign) or biopsy (red star) confirmation of HDLS. Plus sign indicates that DNA was included in the CSF1R sequencing analyses to confirm that mutations segregated with disease. For each subject with DNA available for genetic studies, a unique patient number corresponding to table 1 is included above the subject.
npg l e t t e r s cell-surface expression are unlikely to be affected; however, we cannot exclude such effects at this time. These preliminary findings suggest that the kinase activity of mutant CSF1R is disrupted, probably affecting the phosphorylation of downstream targets. We speculate that mutant CSF1R might assemble into nonfunctional homodimers and wild-type-mutant heterodimers, inducing a dominant-negative disease mechanism.
To address whether CSF1R autophosphorylation is also disrupted in individuals with HDLS, we first subjected blood samples from a healthy control and a subject with HDLS, CA1-1, to CSF1R immunoblotting and observed no apparent difference in total or phosphorylated CSF1R levels (Supplementary Fig. 6a ). In addition, we performed CSF1R immunoblotting of frontal-cortex brain tissue from healthy controls and subjects with HDLS. We also included brain samples from individuals with Alzheimer's disease and amyotrophic lateral sclerosis as neurodegenerative disease controls. Our data showed varied levels of total and phosphorylated CSF1R in these brain samples (Supplementary Fig. 6b) ; however, statistical analysis did not show a significant difference between any of the groups (P > 0.05 for all study groups for each epitope). Although these preliminary in vivo studies do not demonstrate a defect in autophosphorylation, our findings do not necessarily conflict with the data obtained in cultured cells. First, the subjects with HDLS are heterozygous for the CSF1R mutations, and thus, in contrast to our in vitro experiments, the wild-type receptor is still present in these individuals. Second, in our cell-culture experiments, we downregulated CSF1R signaling by serum deprivation to minimize basal receptor activity before stimulation with the CSF-1 ligand. CSF-1 is a serum protein, so without this deprivation in vivo, immediate changes in CSF-1-induced CSF1R autophosphorylation may not be apparent as there may be wild-type receptors at the cell surface that have already been activated. Unfortunately, without access to an immortalized cell line derived from an individual with HDLS, we are currently unable to accurately assess acute receptor activation in vivo. Finally, the postmortem brain samples from subjects with HDLS that we examined show extensive degeneration, leaving the possibility that cells with greater disruption of CSF1R signaling are under-represented in the tissue sample.
Unraveling the genetic etiology of HDLS may contribute to the understanding of other adult-onset leukoencephalopathies. De novo mutations in CSF1R could underlie sporadic cases that have been described with clinical and pathological similarities to HDLS [24] [25] [26] [27] [28] [29] . Future CSF1R mutation screening may also determine whether HDLS and pigmentary orthochromatic leukodystrophy are part of a single clinicopathologic entity, as has recently been suggested 2 . Moreover, the discovery of a mutation in a microglial trophic factor receptor may further elucidate the role of microglia in more common white-matter disorders, particularly those associated with axonal dystrophy such as Binswanger's disease 24, 30 , multiple sclerosis 31 and HIV encephalitis 32 .
Notably, our findings also shed new light on Nasu-Hakola disease (NHD), a rare condition characterized by systemic bone cysts and dementia with striking similarities to HDLS [33] [34] [35] . NHD is caused by recessive loss-of-function mutations in the DAP12-TREM2 protein complex 36, 37 , which was recently implicated in CSF1R signaling, establishing NHD as a primary microglial disorder 38 . We speculate that a partial loss of the CSF1R-DAP12 signaling cascade in microglia is responsible for the neurological phenotypes observed in HDLS l e t t e r s and NHD, whereas a complete loss of this signaling cascade in bone marrow-derived macrophages is needed for the formation of bone cysts observed in NHD. In support of this hypothesis, a partial loss-of-function mutation in TREM2 in a family with early-onset dementia without bone cysts has recently been reported 39 . Of note, no bone cysts were reported in any of the subjects with HDLS we studied, and a bone scan in subject CA1-1 did not show bone fractures, hypomineralization or any other bone-structure abnormalities.
In summary, we have shown that mutations affecting the tyrosine kinase domain of CSF1R underlie the white-matter disease HDLS, establishing HDLS as a member of the recently defined class of primary microglial disorders called microgliopathies 40 . Future molecular studies of CSF1R signaling may provide new insights into microglial physiology and the involvement of this cell type in HDLS and neurodegeneration. Moreover, CSF1R mutation screening in patient series with neurodegenerative disease will allow a Autophosphorylation of several tyrosine residues within the kinase domain of CSF1R is crucial for its subsequent signaling, involved in cell survival and proliferation. We studied CSF1R autophosphorylation in HeLa cells, which do not express detectable levels of CSF-1, thereby minimizing endogenous CSF-1-induced signaling. Shown is a representative western blot of lysates from HeLa cells transfected with CSF1RWT or mutant CSF1R M875T and treated with CSF-1 for 5, 15 or 30 min. Lysates from untreated CSF1R-transfected cells are included as a control; GAPDH immunoreactivity was analyzed to ensure equal protein loading. Total CSF1R immunodetection for both DNA constructs was robust. Further, we observed strong phosphorylation of wild-type CSF1R after 5 min of CSF-1 treatment, which was weaker in the 15-min and 30-min treatments, as determined by immunoblotting using CSF1R phosphospecific tyrosine (p-Tyr) antibodies. In contrast, no CSF1R autophosphorylation at any of the selected tyrosine residues was detected after CSF-1 treatment in CSF1R M875T-transfected cells. Experiments were repeated three times with similar outcomes. Comparable results were obtained using CSF1R mutants CSF1R E633K and CSF1R M766T (supplementary Fig. 5 ). npg l e t t e r s more accurate diagnosis of HDLS and could facilitate detection of presymptomatic individuals, which is indispensable for therapy development and early treatment.
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Subjects.
A detailed description of the families with HDLS and control subjects included in this study is provided in the Supplementary Note. The experiments performed in this study were approved by the Mayo Clinic Institutional Review Board, and all biological samples were obtained after informed consent from the individuals or their guardians. Demographic information for the populations of individuals with neurodegenerative disease included in the CSF1R sequencing analyses is summarized in Supplementary Table 2 .
Demographic information for the affected individuals included in the CSF1R functional analyses is summarized in Supplementary Table 4 .
Linkage analyses. We performed a genome-wide linkage scan using 6,090 SNPs in family VA using the Infinium HumanLinkage-12 microarrays (Illumina). Genotypes were determined with BeadStudio (Illumina). MERLIN 1.0 was used to perform a multipoint nonparametric linkage analysis using the Illumina Linkage-12 allele frequencies. Individuals were considered affected in the analyses on the basis of an autopsy confirmation of HDLS, clinical examination (by Z.K.W.) or medical records combined with an autopsy confirmation of HDLS in an affected offspring. The generated Z scores (and their equivalent lod scores) provided evidence for five potentially linked loci on five different chromosomes, each with a corresponding lod score >1.0 ( Supplementary Fig. 1a ). Parametric analysis was performed on these five loci using an affected-only autosomal-dominant inheritance model. Allele frequencies available from the Illumina Linkage-12 set were used and the disease allele frequency was set at 0.0001.
Exome sequencing. Exome enrichment was conducted largely according to the manufacturer's protocol for the SureSelect Human All Exon Target Enrichment System (Agilent Technologies, version 2.01, based on the methodology described 41 ). Briefly, 3 µg of genomic DNA was fragmented by sonication using the Covaris S2 device to achieve fragments with a mean size of 300 bp. Sonicated DNA was purified using Agencourt's AMPure XP Solid Phase Reversible Immobilization paramagnetic bead (SPRI), and we then polished the DNA ends by removing the 3′ overhangs and filling in the 5′ overhangs using T4 DNA polymerase and Klenow fragment (New England Biolabs). After end polishing, a single adenine base was added to the 3′ end of the DNA fragments using Klenow fragment (3′-to-5′ exo minus). The endrepaired DNA was ligated to the Illumina paired-end adaptors in a standard ligation reaction using T4 DNA ligase and 2-4 µM final concentration of adaptor, depending on the DNA yield after purification after the addition of the adenine. After ligation, samples were purified using SPRI beads, assessed on the Agilent Bioanalyzer and amplified by six PCR cycles. We prepared 500 ng of amplified, purified DNA (DNA library) for hybridization by adding the DNA library to Agilent blocking reagents, denaturing at 95 °C and incubating at 65 °C. All subsequent steps were performed at 65 °C. Hybridization buffer was added to the prepared library and the entire mix was added to an aliquot of the Agilent SureSelect Capture Library and incubated at 65 °C for 24 h. After hybridization, streptavidin-coated magnetic beads were used to purify the RNA-DNA hybrids formed during hybridization. RNA capture material was digested via acid hydrolysis after elution from the purification beads. Neutralized captured DNA was purified, desalted and amplified by 12 PCR cycles using Herculase II Fusion DNA polymerase. Libraries were purified after amplification and assessed using the Agilent Bioanalyzer. Final quantification of the library was performed with the Kapa Biosciences real-time PCR assay. Sequencing was performed as described 42 . After dilution to 10 nM final concentration on the basis of the real-time PCR and bioanalyzer results, the final library stock was used in paired-end cluster generation at a final concentration of 6-8 pM to achieve a cluster density of 600,000/mm 2 (on the Illumina HiSeq2000 instrument). After cluster generation, 50-nt paired-end sequencing was performed using the standard Illumina protocols. For each subject, we obtained >11 Gb of sequence to achieve a 100× median coverage of the targeted exome.
Read mapping and variant analyses.
Raw sequencing data for each individual were mapped to the human reference genome (build hg19) using the Burrows-Wheeler Aligner (BWA version 0.5.81536) 43 . The BWA-aligned sequencing reads were processed by Picard to label PCR duplicates. The Genome Analysis Toolkit (GATK, version 5091) was then used to remove duplicates, perform local realignment and recalibrate map quality scores, producing a 'cleaned' BAM file for each individual. SNP calls were made by the Unified Genotyper module in GATK using the cleaned BAM files. The resulting Variant Call Format (VCF, version 4.0) files were annotated using the GenomicAnnotator module in GATK to identify and label the called variants that were within the targeted coding regions and that overlapped with known and likely benign SNPs reported in dbSNP version 132. The annotated VCF files were then filtered using the GATK variant filter module with a hard filter setting and a custom script for initial filtering. Variant calls that did not pass the following filters were eliminated from the call set: (i) MQ0> = 4&& ((MQ0/ (1.0*DP))>0.1); (ii) QUAL<30.0||QD<5.0||HRun>5||SB>0.00; (iii) cluster size 10; (iv) does not contain dbSNP id; (v) unside the targeted regions.
Sanger sequencing analyses.
Coding exons of HTR4 and CSF1R were PCR-amplified using flanking intronic primers tailed with M13 sequences (Supplementary Table 5 ). PCR products were purified using AMPure (Agencourt Biosciences) and then sequenced in both directions using M13 primers and the Big Dye Terminator version 3.1 Cycle Sequencing kit (Applied Biosystems). Sequencing reactions were purified using CleanSEQ (Agencourt Biosciences) and analyzed on an ABI3730 Genetic Analyzer (Applied Biosystems). DNA sequence variants were identified using Sequencher software (Gene Codes).
Genotyping analyses. All newly discovered CSF1R variants were genotyped in control series using custom-designed Taqman SNP genotyping assays on the 7900HT Fast Real Time PCR system. Genotype calls were made using SDS version 2.2 software (Applied Biosystems). The presence of HTR4 c.80C>T was identified in 660 controls by direct bidirectional sequencing of exon 2 using primers HTR4-2F and HTR4-2R for PCR and M13 primers for sequencing ( Supplementary Table 5 ). cDNA transcript analyses. Total RNA was isolated from brain tissue using the RNeasy Plus kit (Qiagen) or fresh blood using PaxGene Blood RNA kit (PreAnalytix) according to the manufacturer's instructions. Reverse transcription was performed using the Superscript III system (Invitrogen). cDNA was amplified using primers CSF1Rc17F with CSF1Rc20R (families FL2 and CA2) and CSF1Rc11F with CSF1Rc19R (NO) ( Supplementary Table 5 ). PCR products were purified using the multiscreen system (Millipore) and sequenced using M13 sequencing primers and Big Dye chemistry (Applied Biosystems). Sequencing reactions were purified using the Montage system (Millipore) and analyzed on an ABI3730 Genetic Analyzer (Applied Biosystems). Sequence transcripts were analyzed using Sequencher software (Gene Codes).
Mutagenesis of CSF1R cDNA clones.
A cDNA construct encoding human CSF1R was purchased from OriGene (RC205288). The p.Glu633Lys, p.Met766Thr, and p.Met875Thr mutations were introduced independently using the QuikChange site-directed mutagenesis kit (Stratagene) and mutagenesis primers ( Supplementary Table 6 ). Mutation-positive clones were identified by sequencing analysis ( Supplementary Table 6 ) and transformed into DH5α-competent Escherichia coli cells, after which DNA was obtained using the Nucleobond Xtra Maxi Plus EF kit (Clontech).
Cell culture transfection and western blotting. HeLa cells were maintained in Eagle's Minimum Essential Medium supplemented with 10% FBS and 1% penicillin-streptomycin at 37 °C and 5% CO 2 . One day before transfection, cells were plated at 150,000 cells per well in six-well culture dishes. The next day, cells were transfected with 2 µg of tGFP control plasmid DNA (OriGene; PS100010) or CSF1R wild-type (CSF1RWT) or mutant (CSF1R E633K, CSF1R M766T or CSF1R M875T) plasmid DNA using Lipofectamine 2000 transfection reagent (Invitrogen). Two days after transfection, the medium was changed to serum-free medium for 16 h before treatment with 50 ng/ml human recombinant MCSF (R&D Systems). CSF-1 remained in the medium for 5, 15 or 30 min before the cells were harvested in RIPA buffer (Boston BioProducts) for western blotting analysis. HeLa cells without CSF-1 treatment were collected as controls. Cell lysates were diluted in an equivalent volume of npg
